5th Annual Pharmaceutical Leadership Summit 2012 in India Pushes Brand India Image

5^th Annual Pharmaceutical Leadership Summit 2012 in India Pushes Brand India Image

Industry Leaders to Debate on Indian Pharma Industry’s Growth Story & Generic Drive with Complex Issues at Pharmaleaders Annual Summit & Awards 2012

Maharashtra, Mumbai, India, Tuesday, 10^th July 2012. The much awaited leadership event of Pharmaleaders’s Annual meet, 5^th Annual Pharmaceutical Leadership Summit & Business Leadership Awards 2012 has an aptly theme “Brand India”, Beyond Generics - Growth, Challenges & Opportunities to be staged in India’s leading capital of Pharmaceutical Companies, Mumbai. Widely perceived by Industry’s Opinion Leaders & Analysts as the Centre-Point of debating complex & serious issues, the platform will showcase more than 20 Industry Leaders deliberating on crucial topics of great significance. More than 200 CEO’s, Owners of Pharmaceutical Companies, Pharma Academia, Policy Makers, Management Firms, Diplomats along with overseas Companies have blocked their date to attend at the commercial capital of India in Mumbai on Friday, 21^st September at Hotel Hilton Mumbai International Airport, India. Speaking on the Theme Brand India, Satya Brahma, Chairman & Editor-In-Chief of Pharma Leaders magazine said, “While the earlier Summits since last four years debated equally significant Issues , This year’s Debate will assume significance in view of Indian Government’s announcement to provide free medicines & push for Generics, a decision that may reshuffle the business models of both domestic & MNC”s as Branded Medicines will take a beating”.

Considering the life cycle of block-buster molecules having an average of 20 odd years & In an age where billions of dollars are being spent on research for new molecules and drugs, the best Brands are the old Brands that has topped the list. While top 10 Brands in India come from the mix of Domestic Pharma majors & MNC’s, the big debate of Generics, to my mind will not go well with the medical profession as Doctors will not be aware the manufacturers details as many will plunge into it. While, domestic players dominate the rankings with a 65% share by owning 196 brands in the top-300 list. However, despite a limited presence in India (20% of the total domestic sales), MNCs have demonstrated better brand building capabilities and have created 92 of the top-300 brands, and five of top 10 brands sold in the country added Satya.

Some of the Key Issues that will be deliberated at the daylong Summit by the Industry veterans are  

Ø Brand India : Challenges & Opportunities in an era of Global Economy Slowdown

Ø Branded Formulations VS Branded Generics, 2012 Pharmaceutical Diversification Trends

Ø Obama Healthcare Reforms & its Effect in India . Key Challenges.

Ø The Rise of Indian Healthcare Market: Top 10 sales markets by 2020. Key Challenges.

Ø Emerging Pharmaceutical Market in India , Strategic Partnerships Between Domestic and MNC's are the Driving Force.

Ø Is India's Ambitious $5bn Push Deals Blow To Global Firms With Focus On Generic Alternatives Above Branded Drugs

Ø India's Emerging Biotechnology Industry, Partnering And Investment Opportunities.

Ø Neutraceutical & OTC Sector : The European Market Challenge

Ø Globalization of Indian Pharma Brands: Key Challenges & Opportunities.

Ø Are we ready for a “Mechanical Artificial Heart “for Indian Patients?  

It is pertinent here to note that India has the highest number of US-FDA approved plants outside the US. Most of these plants have multiple approvals from regulatory authorities in Canada, Australia and Germany. India also holds a strong position in producing generic drugs through reverse engineering.

India has put in place a $5.4 billion policy to provide free medicine to its people, a decision that could change the lives of hundreds of millions, but a ban on branded drugs could backfire. However despite 40 percent of the people living below the poverty line, or $1.25 a day or less. The Govrernment of India’s Policy is laudable only to the extent of concept, the real test will be in implementation. The patent expiry of several major 'blockbuster' drugs, coupled with other factors, will fuel growth of global generic pharmaceuticals market by 2017, a scenario that could be a game changer. The global generic pharmaceuticals market is likely to witness strong growth in the next few years owing to the patent expiration of key blockbuster drugs, and the judicious cost containment efforts of governments and healthcare service providers worldwide.